Advancing Science
Enhancing Outcomes
Emerald Biotechnology España
New non-psychotropic cannabinoids for the treatment of inflammatory and neurodegenerative diseases.
Experts in the discovery of new chemical entities with activity on the endocannabinoid system
Emerald Health Biotechnology España SLU (EHB), a wholly owned subsidiary of Emerald Health Research (Canada), is a preclinical-stage pharmaceutical company based in Córdoba, Spain. EHB is a worldwide pioneer company in the discovery and development of novel cannabinoid derivatives for the treatment of inflammatory and neurodegenerative diseases.
Our preclinical development pipeline is focused on unmet medical needs in the treatment of serious life-threatening conditions and other pathologies.

